Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Change in Cash (2016 - 2025)

Historic Change in Cash for Fennec Pharmaceuticals (FENC) over the last 15 years, with Q3 2025 value amounting to $3.2 million.

  • Fennec Pharmaceuticals' Change in Cash rose 21858.08% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$18.4 million, marking a year-over-year decrease of 16580.35%. This contributed to the annual value of $13.4 million for FY2024, which is 22722.51% up from last year.
  • Fennec Pharmaceuticals' Change in Cash amounted to $3.2 million in Q3 2025, which was up 21858.08% from -$4.0 million recorded in Q2 2025.
  • Fennec Pharmaceuticals' Change in Cash's 5-year high stood at $37.9 million during Q1 2024, with a 5-year trough of -$13.7 million in Q4 2024.
  • Over the past 5 years, Fennec Pharmaceuticals' median Change in Cash value was -$3.2 million (recorded in 2021), while the average stood at -$1.0 million.
  • The largest annual percentage gain for Fennec Pharmaceuticals' Change in Cash in the last 5 years was 80421.62% (2024), contrasted with its biggest fall of 167310.34% (2024).
  • Over the past 5 years, Fennec Pharmaceuticals' Change in Cash (Quarter) stood at -$3.0 million in 2021, then tumbled by 102.1% to -$6.0 million in 2022, then surged by 114.55% to $870000.0 in 2023, then plummeted by 1673.1% to -$13.7 million in 2024, then soared by 123.69% to $3.2 million in 2025.
  • Its Change in Cash stands at $3.2 million for Q3 2025, versus -$4.0 million for Q2 2025 and -$4.0 million for Q1 2025.